Cost-Effectiveness of More Intensive Blood Pressure Treatment in Patients with High Risk of Cardiovascular Disease in Saudi Arabia: A Modelling Study of Meta-Analysis
Objective. The current literature suggests that more intensive blood pressure (BP) treatment is clinically more effective than less intensive treatment in patients at high risk for cardiovascular disease (CVD). In this analysis, we evaluated the potential clinical benefit and cost-effectiveness of m...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | International Journal of Hypertension |
| Online Access: | http://dx.doi.org/10.1155/2019/6019401 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832563280827121664 |
|---|---|
| author | Ziyad Almalki Yasser Alatawi Adnan Alharbi Bader Almaklefi Suliman Alfaiz Omar Almohana Yasser Alsaidan Abdullah Alanezi |
| author_facet | Ziyad Almalki Yasser Alatawi Adnan Alharbi Bader Almaklefi Suliman Alfaiz Omar Almohana Yasser Alsaidan Abdullah Alanezi |
| author_sort | Ziyad Almalki |
| collection | DOAJ |
| description | Objective. The current literature suggests that more intensive blood pressure (BP) treatment is clinically more effective than less intensive treatment in patients at high risk for cardiovascular disease (CVD). In this analysis, we evaluated the potential clinical benefit and cost-effectiveness of more intensive BP treatment in patients at high risk of developing CVD over their lifetimes. Methods. A Markov state-transition model was developed for the BP strategies to estimate the lifetime incremental cost-effectiveness ratio (ICER) per quality-adjusted-life-year (QALY) using evidence published from a meta-analysis. The other model inputs were retrieved from previous studies. Estimated costs were collected from five hospitals in Riyadh. The model used a lifetime framework adopting Saudi payer perspective and applied a 3% annual discount rate. Sensitivity analysis was conducted using one-way and probabilistic sensitivity analysis (PSA) to evaluate the robustness and uncertainty of the estimates. Results. Treating 10,000 patients with high CVD risk with more intensive BP therapy would avert a total of 873 CV events over their remaining lifetimes as compared with a less intensive strategy. The projections showed that more intensive BP therapy would be cost-effective compared to the less intensive strategy with incremental costs per QALY of $20,358. Probabilistic sensitivity analysis suggested more intensive control would be cost-effective compared with the less intensive control of BP 87.25 % of the time. Conclusion. The result of this study showed that more intensive BP treatment appears to be a cost-effective choice for patients with a high risk of CVD in Saudi Arabia when compared with a less intensive BP strategy. Thus, this finding provides strong evidence for the adoption of this strategy within the Saudi healthcare system. |
| format | Article |
| id | doaj-art-346311d900ee45c5ae22740a26c85ae5 |
| institution | Kabale University |
| issn | 2090-0384 2090-0392 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Hypertension |
| spelling | doaj-art-346311d900ee45c5ae22740a26c85ae52025-02-03T01:20:29ZengWileyInternational Journal of Hypertension2090-03842090-03922019-01-01201910.1155/2019/60194016019401Cost-Effectiveness of More Intensive Blood Pressure Treatment in Patients with High Risk of Cardiovascular Disease in Saudi Arabia: A Modelling Study of Meta-AnalysisZiyad Almalki0Yasser Alatawi1Adnan Alharbi2Bader Almaklefi3Suliman Alfaiz4Omar Almohana5Yasser Alsaidan6Abdullah Alanezi7Department of Clinical Pharmacy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, Riyadh, Saudi ArabiaDepartment of Clinical Pharmacy, College of Pharmacy, Umm Al-Qura University, Mecca, Riyadh, Saudi ArabiaDepartment of Clinical Pharmacy, College of Pharmacy, Umm Al-Qura University, Mecca, Riyadh, Saudi ArabiaDepartment of Clinical Pharmacy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, Riyadh, Saudi ArabiaDepartment of Clinical Pharmacy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, Riyadh, Saudi ArabiaDepartment of Clinical Pharmacy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, Riyadh, Saudi ArabiaDepartment of Clinical Pharmacy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, Riyadh, Saudi ArabiaDepartment of Clinical Pharmacy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, Riyadh, Saudi ArabiaObjective. The current literature suggests that more intensive blood pressure (BP) treatment is clinically more effective than less intensive treatment in patients at high risk for cardiovascular disease (CVD). In this analysis, we evaluated the potential clinical benefit and cost-effectiveness of more intensive BP treatment in patients at high risk of developing CVD over their lifetimes. Methods. A Markov state-transition model was developed for the BP strategies to estimate the lifetime incremental cost-effectiveness ratio (ICER) per quality-adjusted-life-year (QALY) using evidence published from a meta-analysis. The other model inputs were retrieved from previous studies. Estimated costs were collected from five hospitals in Riyadh. The model used a lifetime framework adopting Saudi payer perspective and applied a 3% annual discount rate. Sensitivity analysis was conducted using one-way and probabilistic sensitivity analysis (PSA) to evaluate the robustness and uncertainty of the estimates. Results. Treating 10,000 patients with high CVD risk with more intensive BP therapy would avert a total of 873 CV events over their remaining lifetimes as compared with a less intensive strategy. The projections showed that more intensive BP therapy would be cost-effective compared to the less intensive strategy with incremental costs per QALY of $20,358. Probabilistic sensitivity analysis suggested more intensive control would be cost-effective compared with the less intensive control of BP 87.25 % of the time. Conclusion. The result of this study showed that more intensive BP treatment appears to be a cost-effective choice for patients with a high risk of CVD in Saudi Arabia when compared with a less intensive BP strategy. Thus, this finding provides strong evidence for the adoption of this strategy within the Saudi healthcare system.http://dx.doi.org/10.1155/2019/6019401 |
| spellingShingle | Ziyad Almalki Yasser Alatawi Adnan Alharbi Bader Almaklefi Suliman Alfaiz Omar Almohana Yasser Alsaidan Abdullah Alanezi Cost-Effectiveness of More Intensive Blood Pressure Treatment in Patients with High Risk of Cardiovascular Disease in Saudi Arabia: A Modelling Study of Meta-Analysis International Journal of Hypertension |
| title | Cost-Effectiveness of More Intensive Blood Pressure Treatment in Patients with High Risk of Cardiovascular Disease in Saudi Arabia: A Modelling Study of Meta-Analysis |
| title_full | Cost-Effectiveness of More Intensive Blood Pressure Treatment in Patients with High Risk of Cardiovascular Disease in Saudi Arabia: A Modelling Study of Meta-Analysis |
| title_fullStr | Cost-Effectiveness of More Intensive Blood Pressure Treatment in Patients with High Risk of Cardiovascular Disease in Saudi Arabia: A Modelling Study of Meta-Analysis |
| title_full_unstemmed | Cost-Effectiveness of More Intensive Blood Pressure Treatment in Patients with High Risk of Cardiovascular Disease in Saudi Arabia: A Modelling Study of Meta-Analysis |
| title_short | Cost-Effectiveness of More Intensive Blood Pressure Treatment in Patients with High Risk of Cardiovascular Disease in Saudi Arabia: A Modelling Study of Meta-Analysis |
| title_sort | cost effectiveness of more intensive blood pressure treatment in patients with high risk of cardiovascular disease in saudi arabia a modelling study of meta analysis |
| url | http://dx.doi.org/10.1155/2019/6019401 |
| work_keys_str_mv | AT ziyadalmalki costeffectivenessofmoreintensivebloodpressuretreatmentinpatientswithhighriskofcardiovasculardiseaseinsaudiarabiaamodellingstudyofmetaanalysis AT yasseralatawi costeffectivenessofmoreintensivebloodpressuretreatmentinpatientswithhighriskofcardiovasculardiseaseinsaudiarabiaamodellingstudyofmetaanalysis AT adnanalharbi costeffectivenessofmoreintensivebloodpressuretreatmentinpatientswithhighriskofcardiovasculardiseaseinsaudiarabiaamodellingstudyofmetaanalysis AT baderalmaklefi costeffectivenessofmoreintensivebloodpressuretreatmentinpatientswithhighriskofcardiovasculardiseaseinsaudiarabiaamodellingstudyofmetaanalysis AT sulimanalfaiz costeffectivenessofmoreintensivebloodpressuretreatmentinpatientswithhighriskofcardiovasculardiseaseinsaudiarabiaamodellingstudyofmetaanalysis AT omaralmohana costeffectivenessofmoreintensivebloodpressuretreatmentinpatientswithhighriskofcardiovasculardiseaseinsaudiarabiaamodellingstudyofmetaanalysis AT yasseralsaidan costeffectivenessofmoreintensivebloodpressuretreatmentinpatientswithhighriskofcardiovasculardiseaseinsaudiarabiaamodellingstudyofmetaanalysis AT abdullahalanezi costeffectivenessofmoreintensivebloodpressuretreatmentinpatientswithhighriskofcardiovasculardiseaseinsaudiarabiaamodellingstudyofmetaanalysis |